Creative Medical Technology (NASDAQ:CELZ) Stock Price Up 1.4% – What’s Next?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)’s stock price rose 1.4% during trading on Monday . The stock traded as high as $2.32 and last traded at $2.17. Approximately 92,849 shares traded hands during trading, an increase of 54% from the average daily volume of 60,117 shares. The stock had previously closed at $2.14.

Analysts Set New Price Targets

CELZ has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Monday, December 29th. Wall Street Zen lowered Creative Medical Technology from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Creative Medical Technology has an average rating of “Reduce”.

Creative Medical Technology Stock Up 1.4%

The business has a 50-day moving average price of $1.93 and a 200-day moving average price of $2.45. The firm has a market capitalization of $8.02 million, a PE ratio of -0.84 and a beta of 1.94.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings data on Friday, March 20th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.43). The company had revenue of $0.00 million during the quarter. On average, equities research analysts anticipate that Creative Medical Technology Holdings, Inc. will post -3.19 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission (SEC). 1.42% of the stock is owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.